According to DSM-5-TR criteria, BED severity is classified as mild (1-3 episodes/week), moderate (4-7 episodes/week), or severe (8+ episodes/week), with each level requiring appropriate treatment intensity
The risk is real but substantially modifiable which is another argument for supervised rather than unsupervised GLP-1 use
If you are unsure whether your medication is the primary factor, a dermatologist can help identify what is driving the shedding
Glucagon Like Peptide-1 Receptor Expression in the Human Thyroid Gland
Weight loss medications have evolved significantly over the past decade
PlexusDx's $99 genetic test maps your GLP1R, GIPR, FTO, and MC4R variants across 150+ insights, predicting whether you'll respond optimally to semaglutide, tirzepatide, or dual protocols